The current global demand for biopharmaceuticals is over USD 300 billion, with an estimated growth of ≥ 12% annually. While MAb processes have become much more efficient, production of mRNA and viral vectors is still hindered by the requirement for a reliable source of high-quality plasmid DNA (pDNA), which typically requires multiple purification steps to achieve.